The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspects

https://doi.org/10.1016/0163-7258(90)90025-WGet rights and content

Abstract

It has been established that the metabolism of more than twenty drugs, including antiarrhythmics, β-adrenoceptor antagonists, antidepressants, opiates and neuroleptics is catalyzed by cytochrome P-450dbl. The activity of this P-450 isozyme is under genetic rather than environmental control. This article discusses the therapeutic implications for each of the classes of drugs affected by this genetic polymorphism in drug metabolism. Not only are the problems associated with poor metabolizers who are unable to metabolize the compounds discussed, but it is also emphasized that it is difficult to attain therapeutic plasma concentrations for some drugs in high activity extensive metabolizers.

References (125)

  • U.A. Meyer et al.

    The genetic polymorphism of debrisoquine/sparteine metabolism—Metabolism mechanisms

    Pharmac. Ther.

    (1990)
  • B.W. Newton et al.

    Sparteine sulphate: A potent capricious oxytoxic

    Am. J. Obstet. Gynec.

    (1966)
  • S.V. Otton et al.

    Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs

    Life Sci.

    (1984)
  • G. Pfaff et al.

    Interindividual variation in the metabolism of dextromethorphan

    Int. J. Pharmaceut.

    (1983)
  • R.R. Shah et al.

    Prediction of subclinical perhexiline neuropathy in a patient with inborn error of debrisoquine hydroxylation

    Am. Heart. J.

    (1983)
  • G. Alvan et al.

    Relationship of N-demethylation of amiflamine and its metabolite to debrosoquine hydroxylation polymorphism

    Clin. Pharmac. Ther.

    (1984)

  • Editorial: Polymorphic drug oxidation—Much ado about nothing?

    Lancet

    (1984)
  • T.D. Arias et al.

    A preliminary note on the transient polymorphic oxidation of sparteine in the Ngawbe Guaymi Amerindians: A case of genetic divergence with tentative phyogenetic time frame for the pathway

    Clin. Pharmac. Ther.

    (1988)
  • T.D. Arias et al.

    The oxidative metabolism of sparteine in the Cuna Amerindians of Panama: Absence of evidence for deficient metabolizers

    Clin. Pharmac. Ther.

    (1988)
  • P.J. Bacon et al.

    Cardiovascular responses to metipranolol and timolol eyedrops in healthy volunteers

    Br. J. clin. Pharmac.

    (1989)
  • A.E. Balant-Gorgia et al.

    Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites

    Eur. J. clin. Pharmac.

    (1986)
  • J. Beckmann et al.

    Is there a genetic factor in flecainide toxicity?

    Br. med. J.

    (1988)
  • J. Benitez et al.

    Debrisoquin oxidation polymorphism in a Spanish population

    Clin. Pharmac. Ther.

    (1988)
  • W.M. Bennet

    Guide to drug dosage in renal failure

  • L. Bertilsson et al.

    Extremely rapid hydroxylation of debrisoquine. A case report with implication for treatment with nortriptyline and other tricyclic antidepressants

    Ther. Drug Monit.

    (1985)
  • L. Bertilsson et al.

    Rapid conjugation in an extremely rapid hydroxylator of debrisoquine: A case report supporting a corregulation of certain phase I and II metabolic reactions

    Ther. Drug Monit

    (1988)
  • K. Brosen

    Sparteine oxidation polymorphism in Greenlanders living in Denmark

    Br. J. clin. Pharmac.

    (1986)
  • K. Brosen et al.

    First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype

    Clin. Pharmac. Ther.

    (1988)
  • K. Brosen et al.

    Sparteine oxidation polymorphism in Denmark

    Acta pharmac. Toxic.

    (1985)
  • K. Brosen et al.

    Steady-state levels of imipramine and its metabolites: Significance of dose-dependent kinetics

    Eur. J. clin. Pharmac.

    (1986)
  • K. Brosen et al.

    Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphisms

    Eur. J. clin. Pharmac.

    (1986)
  • K. Brosen et al.

    Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment

    Pharmac. Toxic.

    (1987)
  • D.W.J. Clark et al.

    Adverse effects from metoprotol are not generally associated with oxidation status

    Br. J. clin. Pharmac.

    (1984)
  • R.G. Cooper et al.

    Polymorphic hydroxylation of perhexiline maleate in man

    J. med. Genet.

    (1984)
  • M.L. Dahl-Puustinen et al.

    Disposition of perphenazine is related to the polymorphic debrisoquin hydroxylation in man

    Clin. Pharmac. Ther.

    (1989)
  • P. Dayer et al.

    Stereo- and regioselective of hepatic oxidation in man—effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation

    Eur. J. clin. Pharmac.

    (1986)
  • P. Dayer et al.

    Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450dbl activity

    Clin. Pharmac. Ther.

    (1989)
  • J. Desmeules et al.

    Impact of genetic and environmental factors on codeine analgesia

    Clin. Pharmac. Ther.

    (1989)
  • B. Dick et al.

    Drug hydroxylation disorders (debrisoquine type) in a random sample of the Swiss population

    Schweiz. Med. Wochenschr.

    (1982)
  • M. Eichelbaum

    Ein neuentdeckter Defekt im Arzneimittel-stoffwechsel des Menschen: Die fehlende N-Oxidation des Spartein

    (1975)
  • M. Eichelbaum et al.

    Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans

    Eur. J. clin. Pharmac.

    (1985)
  • M. Eichelbaum et al.

    Defective N-oxidation of sparteine in man: a new pharmacogenetic defect

    Eur. J. clin. Pharmac.

    (1979)
  • M. Eichelbaum et al.

    The influence of enzyme induction on polymorphism sparteine oxidation

    Br. J. clin. Pharmac.

    (1986)
  • M. Eichelbaum et al.

    The genetic polymorphism of sparteine metabolism

    Xenobiotica

    (1986)
  • D.A. Evans et al.

    A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population

    J. met. Genet.

    (1980)
  • D.A. Evans et al.

    The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions

    J. med. Genet.

    (1983)
  • M.D. Feher et al.

    Single dose pharmacokinetics of tomoxetibe in poor and extensive metabolisers of debrisoquine

    Br. J. clin. Pharmac.

    (1988)
  • B. Gachalyi et al.

    Debrisoquine hydroxylation polymorphism in Hungary

    Orv. Hetil.

    (1986)
  • A. Gaedick et al.

    Frequencies of the different mutant alleles of the sparteine/debrisoquine polymorphism

    Naunyn-Schmiedebergs Arch. Pharmac.

    (1989)
  • C.H. Gleiter et al.

    Discovery of altered pharmacokinetics of CGP 15210G in poor hydroxylators of debrisoquine during early drug development

    Br. J. clin. Pharmac.

    (1985)

    • Cited by (379)

    • Pathways of drug metabolism

      2021, Atkinson's Principles of Clinical Pharmacology

    • 7.13 Oxidation: Stereoselective Oxidations with Cytochrome P450 Monooxygenases

      2012, Comprehensive Chirality

    • Rat CYP2D2, not 2D1, is functionally conserved with human CYP2D6 in endogenous morphine formation

      2012, FEBS Letters
      Citation Excerpt :

      Human CYP2D6 is involved in the oxidation of about 30% of clinically relevant drugs including the morphine precursor codeine [1,2]. The enzyme has been connected to a phenomenon known as the debrisoquine/sparteine metabolism of drug oxidation which is caused by aberrant metabolism patterns due to the absence or deficiency of functional allelic variants of CYP2D6 [3]. At least 112 allelic variants of CYP2D6 have been described since the discovery of the genetic polymorphism resulting in a total of four individual phenotypes: poor, intermediate, extensive and ultrarapid metabolizers [4].

    • Pharmacogenetics-in veterinary-anesthesia-and analgesia

      2024, Pharmacology in Veterinary Anesthesia and Analgesia

    • Relevance of pharmacogenetics and pharmacogenomics in veterinary clinical practice: A review

      2024, Animal Genetics

    • Development of a Sensitive and Rapid HPLC–MS Method for Dihydrocodeine and Dihydromorphine: Application to Bioequivalence Studies

      2022, Journal of Chromatographic Science
    View all citing articles on Scopus
    View full text
    Copyright © 1990 Published by Elsevier Inc.